OrbiMed Advisors sold 860,123 shares of Enliven Therapeutics for approximately $39.0 million at an average price of $45.36 per share on June 22, 2026. The sale represented 11.60% of OrbiMed's total indirect holdings, reducing its indirect stake from 7,415,225 to 6,555,102 shares. All remaining shares are held indirectly through OrbiMed-managed entities. Enliven's stock has surged roughly 130% over the past year, and the company recently announced positive Phase 1 data for its lead candidate ELVN-001, with plans to launch a pivotal Phase 3 trial in the second half of 2026. The biotech ended the first quarter with $452.4 million in cash and later closed an upsized public offering generating approximately $460 million in gross proceeds.
Enliven Therapeutics Inc.OrbiMed sold $39M of stock, reducing its stake, which is a negative signal for the stock.